Peter Dudek

Peter Dudek has a diverse work experience in the biotechnology and pharmaceutical industry. Peter is currently serving as a Board Director at InduPro, a position they have held since February 2022. Prior to this, they held the role of Board Observer at Photys Therapeutics starting in December 2021. Peter also served as a Board Director at Caraway Therapeutics, Tallac Therapeutics, Mozart Therapeutics, Ambagon Therapeutics, and LifeMine Therapeutics.

Peter's previous experience includes working at Merck, where they held various positions in the MRL Ventures Fund. Peter started as a Partner in April 2018 and later became the President & Managing Partner in March 2021. Additionally, they have served as a Board Observer at Carisma Therapeutics and HotSpot Therapeutics, Inc.

Overall, Peter Dudek has a strong background in board leadership and strategic management within the biotech industry.

Peter Dudek began their education at WDHS from 1992 to 1996, where they did not pursue any specific degree or field of study. Peter then attended Capilano University from 1996 to 1998 and obtained an Associate of Science degree in Science. Following that, they enrolled in The University of British Columbia from 1998 to 2000 and completed a Bachelor of Science (Hons) in Molecular Microbiology and Immunology. Continuing their educational journey, they attended the University of Geneva from 2000 to 2006 and attained a Doctor of Philosophy degree in Cell Biology. Later on, in 2007, they enrolled at Saïd Business School, University of Oxford, for a period of two years and studied Building a Business and Medical Innovation. Lastly, in 2009, Peter attended the University of Oxford for the Technology Spin-out Management Programme, although the specific degree obtained is not mentioned.